Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | PIONEER: avapritinib in patients with indolent systemic mastocytosis

Cem Akin • 10 Jun 2020
EHA 2020
Myeloproliferative Neoplasms Systemic Mastocytosis Avapritinib
PIONEER

Cem Akin MD, PhD, of the University of Michigan, Ann Arbor, MI, discusses the results of PIONEER (NCT03731260), a randomized, double-blind, placebo-controlled, Phase II study of avapritinib in patients with indolent systemic mastocytosis. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Cem Akin

1:43
ddPCR detects KIT D816V mutations with high sensitivity in systemic mastocytosis
Cem Akin • 11 Dec 2020
5:14
Avapritinib for indolent systemic mastocytosis in the PIONEER trial
Cem Akin • 11 Dec 2020
1:58
Mastocytosis: impact of COVID-19 on clinical practice
Cem Akin • 10 Jun 2020

Related Videos

2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
2:52
JAK inhibitor combination therapy for the treatment of myelofibrosis
Ruben Mesa • 9 Dec 2023
1:30
XPORT-MF-034: selinexor + ruxolitinib combination therapy for MF
John Mascarenhas • 10 Dec 2023
1:38
Pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
John Mascarenhas • 10 Dec 2023
The content of VJHemOnc is intended for healthcare professionals